Alembic Pharmaceuticals Ltd

- There is no specific mention of any current or future new fundraising through debt or equity in the transcript. - Gross debt stood at INR 1,361 crores, broadly in line with December levels, indicating no significant new borrowing. - Capital expenditure for FY '27 is expected to be INR 300-350 crores, directed towards capacity, debottlenecking, and replacement capex, with no indication of additional fundraising to support this. - The company is focusing on capital-efficient execution and working capital management. - Investments are mainly focused on R&D (INR 750-800 crores) and in-licensing for branded business, funded from existing resources. - No guidance or mention of plans for raising funds through equity or additional debt was provided during the call.

- Alembic Pharmaceuticals is broadly done with all major capex, including peptide-related investments, which were part of ongoing API facility upgrades rather than dedicated peptide capex. - The branded business, including U.S. specialty branded operations like Pivya, does not require significant capex; investments are primarily in in-licensing products. - For FY '27, capital expenditure is expected in the range of INR 300-350 crores, focused on capacity expansion, debottlenecking, and replacement capex. - There will be continued, though measured, R&D investments (~INR 750-800 crores) to support complex products and expansion of the branded business. - New product launches, increased utilization of F2 and F3 facilities, and contract manufacturing deals contribute to strategic growth without significant new capex. - Strategic focus remains on quality portfolio additions, operating leverage, working capital management, and calibrated brand business expansion.

- Alembic Pharmaceuticals targets low double-digit consolidated revenue growth in FY '27, driven by internal performance improvements amid stable external market conditions. - U.S. business expected to grow 10-15% in INR terms (approximately 7-8% in constant currency). - Rest of World (ex-U.S.) markets projected to grow 15%+ driven by new product launches and expanding footprints. - API business anticipated to grow around 10%, supported by volume increases. - India business aims to improve growth momentum, targeting growth closer to the overall market. - New product launches, especially Day 1 and First-to-File opportunities, along with contract manufacturing, will support volume growth. - The U.S. branded business is in a launch phase, expected to scale and contribute meaningfully in the next few quarters. - R&D investments continue to underpin growth through innovation and complex product development.

- Alembic expects low double-digit consolidated top-line growth in FY '27 driven by international generics, API, and India businesses. - U.S. business projected to grow 10-15% in INR terms; ex-U.S. markets expected to grow 15+%. - EBITDA margins expected to improve: core business margins to offset drag from the new U.S. branded business (Pivya), which may impact margins by 100-150 basis points initially. - R&D spends will increase to INR 750-800 crores with focus on complex products and peptide pipeline, measured by IRR, aiming for improved medium-term returns. - The company targets a return to ~20% EBITDA margins over a 2-3 year period, with FY '27 anticipated as a year where margin improvement begins. - Earnings growth driven by improved operating leverage, cost savings, and selective investments in differentiated portfolios. - Profit after tax grew 16% in FY '26, with expectations of continued profitability improvement aligned with growth and margin expansion.

The transcript from Alembic Pharmaceuticals Limited's Q4 FY '26 Earnings Conference Call does not explicitly mention the current or expected order book or pending orders. However, the following related points can be inferred: - Alembic expects product launches in the U.S. and ex-U.S. markets to be phased through FY '27, indicating an active pipeline for launches. - The company mentioned having a portfolio of 5-6 peptide filings, with two already filed and others ongoing, suggesting pending developmental projects. - Contract manufacturing deals for F2 and F3 facilities are already in progress, contributing to revenue in FY '27, implying active orders or partnerships. - Alembic is pursuing in-licensing on the branded side to build the portfolio, indicating ongoing and future product additions. - Overall business growth guidance points to a low double-digit consolidated revenue growth for FY '27, reflecting expected increasing order flow and market activity. No specific order book values or exact pending order quantities were disclosed.